Frederick Magezi
Impact in
- Infectious Diseases top 2%
- COVID-19 Clinical Research Studies
- SARS-CoV-2 and COVID-19 Research
- Internal Medicine top 10%
- Venous Thromboembolism Diagnosis and Management
Papers in
-
- COVID-19 Clinical Research Studies 8
-
- Acute Ischemic Stroke Management 2
Frederick Magezi
11 papers receiving 1.4k citations
Frederick Magezi's Hit Papers
Peers
Comparison fields: 5 of 84
- Infectious Diseases 962
- Internal Medicine 28
- Epidemiology 158
- Neurology 59
- Statistics and Probability 37
Countries citing papers authored by Frederick Magezi
This map shows the geographic impact of Frederick Magezi's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Frederick Magezi with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Frederick Magezi more than expected).
Fields of papers citing papers by Frederick Magezi
This network shows the impact of papers produced by Frederick Magezi. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Frederick Magezi. The network helps show where Frederick Magezi may publish in the future.
Co-authors
The 1 scholars most cited alongside Frederick Magezi, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.
All Works
| # | Work | ||
|---|---|---|---|
| 1 | Convalescent plasma in patients admitted to hospital with COVID-19 (RECOVERY): a randomised controlled, open-label, platform trial Hit paper breakdown → | 2021 | 393 |
| 2 | Casirivimab and imdevimab in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial Hit paper breakdown → | 2022 | 282 |
| 3 | Baricitinib in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial and updated meta-analysis Hit paper breakdown → | 2022 | 231 |
| 4 | 2021 | 213 | |
| 5 | 2019 | 155 | |
| 6 | Higher dose corticosteroids in patients admitted to hospital with COVID-19 who are hypoxic but not requiring ventilatory support (RECOVERY): a randomised, controlled, open-label, platform trial Hit paper breakdown → | 2023 | 84 |
| 7 | 2023 | 25 | |
| 8 | 2019 | 24 | |
| 9 | 2024 | 24 | |
| 10 | 2025 | 5 | |
| 11 | 2025 | 2 | |
| 12 | 2019 | 0 |
About Frederick Magezi
Frederick Magezi is a scholar working on Infectious Diseases, Epidemiology, Cardiology and Cardiovascular Medicine, Surgery and Nuclear Energy and Engineering, having authored 12 papers that have together received 1.4k indexed citations. Recurring topics across this work include COVID-19 Clinical Research Studies (8 papers), Acute Ischemic Stroke Management (2 papers), Atrial Fibrillation Management and Outcomes (1 paper) and Kawasaki Disease and Coronary Complications (1 paper). The work is most often cited by research in Infectious Diseases (962 citations), Internal Medicine (28 citations), Epidemiology (158 citations), Neurology (59 citations) and Statistics and Probability (37 citations). Frederick Magezi has collaborated with scholars based in United Kingdom, Vietnam and Australia. Frequent co-authors include Martyn Patel. Their work appears in journals such as The Lancet, The Lancet Child & Adolescent Health, Journal of the American Heart Association, EClinicalMedicine and The Lancet Infectious Diseases.
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.